Aspirin and the risk of prostate cancer

Eur J Cancer Prev. 2006 Feb;15(1):43-5. doi: 10.1097/01.cej.0000180665.04335.de.

Abstract

Epidemiological studies have suggested that aspirin may have a protective effect against prostate cancer, but the evidence is still limited and inconsistent. The role of aspirin in prostate cancer risk was analysed in a multicentric case-control study conducted in Italy between 1991 and 2002, including 1261 incident cases of carcinoma of the prostate and 1131 hospital controls. A total of 115 (9.1%) cases versus 90 (8.0%) controls reported regular aspirin use. The multivariate odds ratio (OR) for regular aspirin users was 1.10 (95% confidence interval (95% CI) 0.81-1.50). No relation was found with duration of use (OR = 1.03 for <5 years, and 1.17 for > or =5 years) and time since first use (OR = 1.03 for <10 years, and 1.35 for > or =10 years). These findings do not support a protective role of regular aspirin use on prostate cancer risk.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage*
  • Aspirin / administration & dosage*
  • Case-Control Studies
  • Cyclooxygenase Inhibitors / administration & dosage*
  • Humans
  • Italy / epidemiology
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Odds Ratio
  • Prostatic Neoplasms / epidemiology
  • Prostatic Neoplasms / prevention & control*
  • Risk

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Cyclooxygenase Inhibitors
  • Aspirin